EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses

A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses

by Elena Iemma | Nov 27, 2023

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

by Elena Iemma | Sep 22, 2023

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology
Identification of immunodominant T cell epitopes induced by natural Zika virus infection

Identification of immunodominant T cell epitopes induced by natural Zika virus infection

by Elena Iemma | Aug 30, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

by Elena Iemma | Jul 27, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect
Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics Using in Silico and in Vitro Methods

Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics Using in Silico and in Vitro Methods

by Elena Iemma | May 1, 2023

Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics Using in silico and in vitro Methods
« Older Entries

Recent Posts

  • Hey Hey! Hallo! This is a two-way conversation!
  • EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum
  • Visits from the FBI and SEC… and Fearless Science
  • Dreaming of Peptides (and Hello from Tokyo!)
  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562